CL2012003091A1 - Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas. - Google Patents

Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas.

Info

Publication number
CL2012003091A1
CL2012003091A1 CL2012003091A CL2012003091A CL2012003091A1 CL 2012003091 A1 CL2012003091 A1 CL 2012003091A1 CL 2012003091 A CL2012003091 A CL 2012003091A CL 2012003091 A CL2012003091 A CL 2012003091A CL 2012003091 A1 CL2012003091 A1 CL 2012003091A1
Authority
CL
Chile
Prior art keywords
lupus erythematosus
treatment
apollolosus
thymid
subacute
Prior art date
Application number
CL2012003091A
Other languages
English (en)
Spanish (es)
Inventor
Gergely Peter
Wallstrom Erik
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42199281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2012003091A1 publication Critical patent/CL2012003091A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/30Sulfides having the sulfur atom of at least one thio group bound to two carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2012003091A 2010-05-06 2012-11-06 Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas. CL2012003091A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10162079 2010-05-06

Publications (1)

Publication Number Publication Date
CL2012003091A1 true CL2012003091A1 (es) 2013-03-22

Family

ID=42199281

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003091A CL2012003091A1 (es) 2010-05-06 2012-11-06 Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas.

Country Status (24)

Country Link
US (1) US20130172297A1 (https=)
EP (1) EP2566470A1 (https=)
JP (1) JP2013530937A (https=)
KR (1) KR20130066630A (https=)
CN (1) CN102869353A (https=)
AU (1) AU2011249784B2 (https=)
BR (1) BR112012028190A2 (https=)
CA (1) CA2795394A1 (https=)
CL (1) CL2012003091A1 (https=)
CR (1) CR20120566A (https=)
CU (1) CU20120154A7 (https=)
EA (1) EA201201514A1 (https=)
EC (1) ECSP12012312A (https=)
IL (1) IL222690A0 (https=)
MA (1) MA34285B1 (https=)
MX (1) MX2012012926A (https=)
NZ (1) NZ603999A (https=)
PE (1) PE20130612A1 (https=)
PH (1) PH12012502418A1 (https=)
SG (1) SG185746A1 (https=)
TN (1) TN2012000509A1 (https=)
TW (1) TW201201814A (https=)
WO (1) WO2011138393A1 (https=)
ZA (1) ZA201207710B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519539B (zh) * 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1431275B1 (en) * 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
MXPA04002679A (es) * 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
KR101003877B1 (ko) 2002-09-19 2010-12-30 교린 세이야꾸 가부시키 가이샤 아미노알코올 유도체와 그 부가염 및 면역 억제제
US7456157B2 (en) 2003-02-18 2008-11-25 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators
JP4716996B2 (ja) * 2003-05-26 2011-07-06 武田薬品工業株式会社 スルホピロール
CN1874996B (zh) 2003-08-28 2011-05-18 诺瓦提斯公司 氨基丙醇衍生物
EP1723138B1 (en) * 2004-02-11 2010-07-14 Basilea Pharmaceutica AG Substituted benzimidazoles and their use for inducing apoptosis
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
SI2295049T1 (sl) * 2005-09-09 2015-03-31 Novartis Ag Zdravljenje avtoimunskih bolezni

Also Published As

Publication number Publication date
CU20120154A7 (es) 2013-03-27
CR20120566A (es) 2013-01-09
PH12012502418A1 (en) 2018-03-21
SG185746A1 (en) 2013-01-30
BR112012028190A2 (pt) 2016-08-02
IL222690A0 (en) 2012-12-31
MX2012012926A (es) 2012-12-17
KR20130066630A (ko) 2013-06-20
ECSP12012312A (es) 2012-12-28
CA2795394A1 (en) 2011-11-10
NZ603999A (en) 2014-06-27
PE20130612A1 (es) 2013-06-06
TN2012000509A1 (en) 2014-04-01
US20130172297A1 (en) 2013-07-04
EA201201514A1 (ru) 2013-05-30
CN102869353A (zh) 2013-01-09
MA34285B1 (fr) 2013-06-01
AU2011249784B2 (en) 2014-03-06
WO2011138393A1 (en) 2011-11-10
AU2011249784A1 (en) 2012-12-20
JP2013530937A (ja) 2013-08-01
ZA201207710B (en) 2013-06-26
TW201201814A (en) 2012-01-16
EP2566470A1 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
UY34851A (es) Inhibidores macrocíclicos de virus flaviviridae
LT3661514T (lt) Mavakamtenas, skirtas naudoti gydant hipertrofinę kardiomiopatiją
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
PL3035936T3 (pl) Pewne jednostki chemiczne, kompozycje i sposoby
MX384420B (es) Cultivo, producción, procesamiento y uso de cannabis de especialidad.
CR20140576A (es) Sintesis de compuestos heterociclicos
GT201200289A (es) 3-sustituido-5-fluoro-4-imino-3,4-dihidropirimidina-2-(1h)-onas como fungicidas
LT2984166T (lt) Kompozicijos, skirtos mpsi gydymui
PL3495473T3 (pl) Sposób rozszczepienia hydrolitycznego zearalenonu i/lub pochodnych zearalenonu przy pomocy polipeptydu, jak i jego zastosowanie
PL2613774T3 (pl) Kombinacja fenoksybenzaminy i polimyksyny E do leczenia zakażeń drobnoustrojowych
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
MX381488B (es) Indoles para su uso en la infección por el virus de la gripe.
IT1400509B1 (it) Apparecchiatura e metodo per il trattamento di disidratazione spinta di fanghi.
EA201490559A1 (ru) Композиция для лечения свища
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
DK3019452T3 (da) Fremgangsmåde for og installation af biologisk denitrifikation af spildevand
MX386150B (es) Tasimelteon para tratar el síndrome de smith-magenis.
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
UA107346C2 (en) Use of nifuratel to treat infections caused by atopobium species
PL3393984T3 (pl) Instalacja i sposób biologicznego przetwarzania odpadów i ścieków organicznych
ES2663096T3 (es) Métodos para el tratamiento del síndrome nefrótico y de afecciones relacionadas
CL2012003091A1 (es) Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas.
CL2012001758A1 (es) Uso de compuestos derivados de 8-hidroxiquinolin-7-carboxamida y sus sales, para el tratamiento y/o prevencion de infecciones fungicas.
UY33542A (es) Uso de teriflunomida para tratar la esclerosis múltiple